Download presentation
Presentation is loading. Please wait.
Published byὩρος Γεωργίου Modified over 5 years ago
1
Tackling Resistance to PI3K Inhibition by Targeting the Epigenome
Shany Koren, Mohamed Bentires-Alj Cancer Cell Volume 31, Issue 5, Pages (May 2017) DOI: /j.ccell Copyright © 2017 Elsevier Inc. Terms and Conditions
2
Figure 1 Activation of ERα-Dependent Transcriptional Programs by PI3K Inhibition Toska et al. suggest a model in which PI3K pathway activation triggers downstream activation of AKT and the phosphorylation of KMT2D, inhibiting its methyltransferase activity. This results in reduced levels of mono- and di-methylated H3K4 (H3K4me1/2) and decreased chromatin accessibility. As a consequence, binding of the ERα-FOXA1-PBX1 complex is attenuated at chromatin, and transcriptional activation of ERα target genes is reduced (left). In contrast, PI3Kα-specific inhibition by BYL719 results in the methylation of H3K4 by KMT2D, increased chromatin accessibility, ERα-FOXA1-PBX1 complex binding at chromatin, and ERα target gene expression (right). RTK, receptor tyrosine kinase; P, phosphorylated sites. Cancer Cell , DOI: ( /j.ccell ) Copyright © 2017 Elsevier Inc. Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.